Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CACNA1C | Q13936 | 5/20 | 0.56 |
| ▸ | CACNA1F | O60840 | 1/20 | 0.51 |
| ▸ | CACNA1D | Q01668 | 1/20 | 0.51 |
| ▸ | CACNA1S | Q13698 | 1/20 | 0.51 |
| ▸ | CYP2C9 | P11712 | 4/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.49 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.49 |
| ▸ | ADORA3 | P0DMS8 | 3/20 | 0.49 |
| ▸ | MEN1 | O00255 | 2/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.49 |
| ▸ | GAA | P10253 | 2/20 | 0.49 |
| ▸ | MAPT | P10636 | 2/20 | 0.49 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.49 |
| ▸ | HPGD | P15428 | 1/20 | 0.49 |
| ▸ | TP53 | P04637 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3004149 | 0.84 | ADORA3 (0.60) | CACNA1CCACNA1FCACNA1DCACNA1SCYP2C9 | |
| SCHEMBL7162565 | 0.81 | CACNA1F (0.72) | CACNA1CCACNA1FCACNA1DCACNA1SCYP2C9 | |
| SCHEMBL4259169 | 0.80 | ALDH1A1 (0.64) | CYP2C9CYP1A2CYP3A4CYP2C19HSD17B10 | |
| SCHEMBL7158453 | 0.78 | ADORA3 (0.55) | CACNA1CCACNA1FCACNA1DCACNA1SCYP2C9 | |
| SCHEMBL7273470 | 0.77 | CACNA1F (0.67) | CACNA1CCACNA1FCACNA1DCACNA1SCYP2C9 | |
| SCHEMBL6137184 | 0.77 | CACNA1C (0.64) | CACNA1CCACNA1FCACNA1DCACNA1SCYP2C9 | |
| SCHEMBL7156628 | 0.77 | CACNA1F (0.80) | CACNA1CCACNA1FCACNA1DCACNA1SCYP2C9 | |
| SCHEMBL10661401 | 0.77 | CACNA1C (0.47) | CACNA1CKDM4EHSD17B10ALDH1A1CASP1 | |
| SCHEMBL11688838 | 0.76 | ADORA3 (0.52) | CACNA1CCACNA1FCACNA1DCACNA1SCYP2C9 | |
| SCHEMBL11837499 | 0.75 | CACNA1F (0.71) | CACNA1CCACNA1FCACNA1DCACNA1SCYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9045428-B2 | Substituted heterocyclic compounds | GILEAD SCIENCES, INC. (US) | 2015-06-02 | — | — | US | disclosed |
| US-8716319-B2 | Substituted heterocyclic compounds | GILEAD SCIENCES, INC. (US) | 2014-05-06 | — | — | US | disclosed |
| US-20130324525-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2013-12-05 | — | — | US | disclosed |
| US-20100197684-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS | GILEAD PALO ALTO, INC. (US) | 2010-08-05 | — | — | US | disclosed |
| US-20090181986-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS | CV THERAPEUTICS, INC. | 2009-07-16 | — | — | US | disclosed |
| US-20090012103-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS | GILEAD SCIENCES, INC. | 2009-01-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100197684-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS | NQO1, GPR119, GLP1R | CACNA1C 1708/4885CACNA1F 2931/4885CACNA1D 1917/4885 |
| US-20130324525-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS | NQO1, GPR119, GLP1R | CACNA1C 1708/4885CACNA1F 2931/4885CACNA1D 1917/4885 |
| US-20090181986-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS | NQO1, GPR119, GLP1R | CACNA1C 1708/4885CACNA1F 2931/4885CACNA1D 1917/4885 |
| US-20090012103-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS | NQO1, GPR119, GLP1R | CACNA1C 1708/4885CACNA1F 2931/4885CACNA1D 1917/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.